Skip to main content

Drug Interactions between momelotinib and st. john's wort

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

St. John's wort momelotinib

Applies to: st. john's wort and momelotinib

MONITOR: Coadministration with potent CYP450 3A4 inducers may decrease the plasma concentration and therapeutic effects of momelotinib. The proposed mechanism is increased metabolism of momelotinib via the CYP450 3A4 isoenzyme. However, momelotinib is metabolized by multiple pathways and so the clinical significance is unclear. In a phase I study, coadministration of multiple doses of rifampin (600 mg once daily) following a single dose of momelotinib (200 mg) reduced the Cmax and AUC of momelotinib by 29% and 46%, respectively, when compared with a single dose of momelotinib (200 mg) plus a single dose of rifampin (600 mg). No data are available for use with other, less potent inducers.

MANAGEMENT: Caution and monitoring for decreased momelotinib efficacy may be required when used concomitantly with potent CYP450 3A4 inducers. An alternative agent with less potential for induction should be considered if possible.

References (5)
  1. (2023) "Product Information. Ojjaara (momelotinib)." GlaxoSmithKline
  2. (2024) "Product Information. Omjjara (momelotinib)." GlaxoSmithKline Australia Pty Ltd
  3. (2024) "Product Information. Ojjaara (momelotinib)." GlaxoSmithKline Inc
  4. Ho YL, Gorycki P, Ferron-Brady G, Martin P, Vlasakakis G (2024) "Clinical assessment of momelotinib drug-drug interactions via CYP3A metabolism and transporters" Clin Transl Sci, 17, p. 1-14
  5. (2025) "Product Information. Omjjara (momelotinib)." GlaxoSmithKline UK Ltd

Drug and food/lifestyle interactions

Moderate

St. John's wort food/lifestyle

Applies to: st. john's wort

GENERALLY AVOID: An isolated case report suggests that foods containing large amounts of tyramine may precipitate a hypertensive crisis in patients treated with St. John's wort. The mechanism of interaction is unknown, as St. John's wort is not thought to possess monoamine oxidase (MAO) inhibiting activity at concentrations achieved in vivo. The case patient was a 41-year-old man who had been taking St. John's wort for seven days prior to presentation at the emergency room with confusion and disorientation. The patient recalled last eating aged cheese and having a glass of red wine approximately 10 hours prior to admission. No other cause of delirium or hypertension could be identified. In addition, alcohol may potentiate some of the pharmacologic effects of St. John's wort. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Until further information is available, patients treated with St. John's wort should consider avoiding consumption of protein foods in which aging or breakdown of protein is used to increase flavor. These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, yogurt, papaya products, meat tenderizers, fava beans, protein extracts, and dietary supplements. Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well. Patients should also be advised to avoid or limit consumption of alcohol.

References (1)
  1. Patel S, Robinson R, Burk M (2002) "Hypertensive crisis associated with St. John's Wort." Am J Med, 112, p. 507-8

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.